Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial

IMPORTANCE: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. OBJECTIVE: To determine the efficac...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JAMA
Κύριοι συγγραφείς: Tap, William D., Wagner, Andrew J., Schöffski, Patrick, Martin-Broto, Javier, Krarup-Hansen, Anders, Ganjoo, Kristen N., Yen, Chueh-Chuan, Abdul Razak, Albiruni R., Spira, Alexander, Kawai, Akira, Le Cesne, Axel, Van Tine, Brian A., Naito, Yoichi, Park, Se Hoon, Fedenko, Alexander, Pápai, Zsuzsanna, Soldatenkova, Victoria, Shahir, Ashwin, Mo, Gary, Wright, Jennifer, Jones, Robin L.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Medical Association 2020
Θέματα:
Original Investigation
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7139275/
https://ncbi.nlm.nih.gov/pubmed/32259228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.1707
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια